Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Clinical trial NCT06393465 · COMPLETED

Trial details

NCT number: NCT06393465
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Start date: 2024-06-15
Primary completion: 2026-04-07
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.